The United Kingdom has given the green light to the first-ever CRISPR treatment, offering a potential cure for sickle cell disease and beta thalassemia.
How does the treatment work?
The therapy, known as Casgevy, involves modifying a patient’s blood stem cells in the lab using CRISPR technology. The edited cells are then reintroduced into the body, replacing malfunctioning proteins with functional ones. Clinical trials have shown promising results, with patients experiencing a significant reduction in severe symptoms.
What are the issues surrounding it?
As the groundbreaking treatment awaits approval in the U.S. and Europe, questions emerge about the potential costs, reaching millions of dollars, and the accessibility for patients, particularly in regions like Africa with limited medical facilities.
As the world anticipates the widespread adoption of CRISPR treatments for genetic disorders, who should bear the financial burden, and how can we ensure equitable access to this groundbreaking technology, especially for those in regions with limited medical infrastructure?
Find the full article at: United Kingdom approves first-ever CRISPR treatment, a cure for sickle cell disease and beta thalassemia